Track market-moving stories before they get noisy

Caisse de depot et placement du Quebec bought a new position in Natera, Inc. (NASDAQ:NTRA – Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,517 shares of the medical research company’s stock, valued at approximately $683,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Natera in the second quarter valued at approximately $2,962,770,000. K.J. Harrison & Partners Inc purchased a new position in Natera during the 2nd quarter worth approximately $5,117,000. Abbot Financial Management Inc. purchased a new position in Natera during the 2nd quarter worth approximately $1,537,000. Eagle Health Investments LP acquired a new stake in Natera during the 2nd quarter valued at approximately $4,302,000. Finally, UBS Group AG lifted its stake in Natera by 19.4% during the 4th quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock valued at $100,538,000 after acquiring an additional 71,355 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades A number of analysts have recently weighed in on NTRA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. TD Cowen boosted their target price on shares of Natera from $325.00 to $340.00 and gave the company a “buy” rating in a research report on Friday, August 7th. UBS Group set a $260.00 price target on shares of Natera in a report on Wednesday, June 24th. The Goldman Sachs Group initiated coverage on shares of Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price target on the stock. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $355.00 price target on shares of Natera in a research report on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average price target of $319.38.

View Our Latest Stock Analysis on Natera Natera Stock Performance Natera stock opened at $326.26 on Monday. The firm has a market cap of $47.03 billion, a PE ratio of -239.90 and a beta of 1.51. Natera, Inc. has a 12 month low of $157.43 and a 12 month high of $343.18. The stock’s 50 day simple moving average is $285.07 and its two-hundred day simple moving average is $233.78.

Natera (NASDAQ:NTRA – Get Free Report) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. During the same period in the previous year, the firm earned ($0.74) EPS. The business’s quarterly revenue was up 37.7% on a year-over-year basis. On average, equities research analysts forecast that Natera, Inc. will post -1.02 EPS for the current year.

Insider Activity In other Natera news, CFO Michael Burkes Brophy sold 478 shares of Natera stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total value of $131,077.16. Following the completion of the transaction, the chief financial officer owned 51,637 shares of the company’s stock, valued at approximately $14,159,898.14. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 3,076 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64. Following the completion of the transaction, the chief executive officer owned 99,897 shares of the company’s stock, valued at approximately $26,611,561.83. This trade represents a 2.99% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 103,472 shares of company stock worth $24,960,134 in the last ninety days. Corporate insiders own 5.05% of the company’s stock.

About Natera (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Recommended Stories Five stocks we like better than Natera Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Bank of Nova Scotia purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 44,200 shares of the medical research company’s stock, valued at approximately $11,998,000.

Other institutional investors have also recently made changes to their positions in the company. Trust Co. of Vermont bought a new position in Natera in the second quarter worth approximately $26,000. Elevation Wealth Partners LLC bought a new stake in Natera during the second quarter valued at about $30,000. Reflection Asset Management bought a new stake in Natera during the fourth quarter valued at about $29,000. Rakuten Securities Inc. purchased a new stake in Natera in the second quarter worth about $35,000. Finally, Palladiem LLC purchased a new stake in Natera in the fourth quarter worth about $31,000. Institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera In other news, insider Solomon Moshkevich sold 3,410 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80. Following the sale, the insider directly owned 129,019 shares of the company’s stock, valued at $34,264,866.02. This represents a 2.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 3,076 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $266.39, for a total value of $819,415.64. Following the transaction, the chief executive officer owned 99,897 shares of the company’s stock, valued at $26,611,561.83. This represents a 2.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 177,955 shares of company stock valued at $40,704,193 over the last three months. Corporate insiders own 5.05% of the company’s stock.

Wall Street Analysts Forecast Growth A number of research analysts have recently weighed in on the company. Stephens lifted their price objective on Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Morgan Stanley reaffirmed an “overweight” rating and set a $355.00 price target on shares of Natera in a report on Monday, August 10th. Guggenheim upped their price target on shares of Natera from $290.00 to $360.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Piper Sandler increased their price objective on shares of Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Finally, Canaccord Genuity Group set a $375.00 price objective on shares of Natera in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $319.38. Get Our Latest Research Report on Natera

Natera Price Performance NTRA stock opened at $327.72 on Tuesday. Natera, Inc. has a 1-year low of $157.43 and a 1-year high of $333.56. The business has a 50 day simple moving average of $276.45 and a two-hundred day simple moving average of $230.09. The company has a market capitalization of $47.24 billion, a price-to-earnings ratio of -240.97 and a beta of 1.51.

Natera (NASDAQ:NTRA – Get Free Report) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.74) earnings per share. Sell-side analysts anticipate that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Natera Company Profile (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

See Also Five stocks we like better than Natera Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain Snowflake Could Be Headed for New Highs Despite Insider Selling MongoDB Is Surging—And the Next Catalyst Is Almost Here Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Avala Global LP acquired a new stake in Natera, Inc. (NASDAQ:NTRA – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 460,000 shares of the medical research company’s stock, valued at approximately $124,867,000. Natera comprises about 4.6% of Avala Global LP’s holdings, making the stock its 6th biggest holding. Avala Global LP owned approximately 0.32% of Natera as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in NTRA. Integrated Wealth Concepts LLC increased its stake in shares of Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC grew its holdings in Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares during the period. Focus Partners Wealth grew its holdings in Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after purchasing an additional 474 shares during the period. Sivia Capital Partners LLC acquired a new position in Natera during the second quarter worth approximately $298,000. Finally, WINTON GROUP Ltd acquired a new position in Natera during the second quarter worth approximately $558,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling at Natera In related news, CEO Steven Leonard Chapman sold 3,076 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $266.39, for a total value of $819,415.64. Following the completion of the sale, the chief executive officer directly owned 99,897 shares in the company, valued at approximately $26,611,561.83. The trade was a 2.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 478 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $274.22, for a total value of $131,077.16. Following the sale, the chief financial officer directly owned 51,637 shares in the company, valued at approximately $14,159,898.14. This trade represents a 0.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 177,955 shares of company stock valued at $40,704,193 in the last three months. Corporate insiders own 5.05% of the company’s stock.

Analyst Upgrades and Downgrades NTRA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised their price objective on Natera from $315.00 to $360.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Piper Sandler increased their price target on Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Canaccord Genuity Group set a $375.00 price target on Natera in a report on Friday, August 7th. Finally, Barclays reaffirmed an “overweight” rating and set a $340.00 price objective on shares of Natera in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $319.38. Check Out Our Latest Analysis on NTRA

Natera Trading Up 0.5% Shares of NASDAQ NTRA opened at $338.45 on Thursday. The firm has a market cap of $48.78 billion, a P/E ratio of -248.86 and a beta of 1.51. Natera, Inc. has a 1-year low of $157.43 and a 1-year high of $340.96. The business’s 50 day moving average is $281.03 and its 200-day moving average is $232.01.

Natera (NASDAQ:NTRA – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm’s quarterly revenue was up 37.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.74) EPS. Analysts forecast that Natera, Inc. will post -1.02 EPS for the current year.

Natera Profile (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Read More Five stocks we like better than Natera Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks?

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs). Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and.

Key Takeaways Natera will use Signatera to assess AGX101 response in a Phase 1 trial for advanced solid tumors.Signatera will track ctDNA over time to assess whether molecular changes can complement imaging.AGX101 targets TM4SF1 in tumor cells and tumor-associated endothelial cells to deliver a cytotoxic payload. Natera (NTRA - Free Report) recently announced a collaboration with Angiex, Inc. to assess treatment response to AGX101, an investigational nuclear-delivered antibody-drug conjugate (ND-ADC), using its Signatera test. The Phase 1 trial is evaluating AGX101 in patients with unresectable, locally advanced or metastatic solid tumors.

Per management, Signatera can provide deeper insights into early biologic responses, helping to advance the understanding of the novel drug class. Natera looks forward to working with the Angiex team to generate molecular response data that could support the development of AGX101 and further the potential of this therapeutic approach.

NTRA Stock Trend Following the NewsFollowing the announcement, shares of NTRA inched up 0.1% at yesterday’s close. Year to date, the stock has gained 47.8% compared with the industry’s 4.1% growth and the S&P 500’s 11.6% rise.

The collaboration is a positive development for Natera as it expands the use of Signatera in an early-stage clinical program involving a novel cancer treatment approach. If longitudinal ctDNA monitoring demonstrates value alongside imaging, it could strengthen the utility of Signatera for treatment response assessment in advanced solid tumors. The collaboration also adds to Natera’s growing network of biopharma relationships, supporting broader adoption of its molecular residual disease (MRD) and molecular monitoring capabilities.

NTRA currently has a market capitalization of $48.79 billion.

Image Source: Zacks Investment Research

More on the NewsAGX101 is designed to target TM4SF1 and deliver a cytotoxic payload to both TM4SF1-expressing tumor cells and tumor-associated endothelial cells. This dual-targeting approach is intended to address cancer cells as well as tumor vasculature. Signatera will be used for longitudinal circulating tumor DNA (ctDNA) monitoring to assess its potential role in monitoring treatment response throughout AGX101 therapy.

Natera’s Signatera test offers a personalized approach to measuring ctDNA and may serve as a complementary tool to radiologic evaluations. Tracking ctDNA levels over time could provide additional insights into treatment response, particularly in cases where imaging detects metabolic or structural changes that may not clearly indicate the presence of viable tumor.

Angiex co-founder and CEO Paul Jaminet, Ph.D., said AGX101 could provide a differentiated treatment option for patients with advanced solid tumors. The collaboration will assess whether longitudinal ctDNA measurements can complement imaging and offer deeper insights into treatment response.

Industry Prospects Favoring the MarketGoing by the data provided by Grand View Research, the global minimal residual disease testing market is predicted to be valued at $3 billion in 2026 and is expected to witness a CAGR of 13.2% through 2033.

Factors like the increasing adoption of MRD testing in oncology care, rising cancer burden, growing adoption of precision medicine and increasing use of advanced technologies like next-generation sequencing and PCR are supporting the market’s growth.

Other NewsNatera recently collaborated with Kupando Therapeutics to support a Phase 1 clinical trial evaluating circulating tumor DNA (ctDNA) dynamics in patients with advanced skin cancers. The collaboration will use Natera’s Latitude tissue-free MRD test to monitor treatment response to KUP-101, Kupando’s investigational immunotherapy targeting innate immune activation.

Natera’s MRD test, Signatera, received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR) for use across multiple types of cancer, including gastrointestinal, genitourinary, breast, skin, gynecological, head and neck, non-small cell lung cancer, diffuse large B-cell lymphoma, indolent non-Hodgkin's lymphomas and pan-cancer immunotherapy monitoring.

NTRA’s Zacks Rank & Key PicksCurrently, NTRA carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

When you look at Stanley Druckenmiller's latest 13F, the headline names are familiar. He added Amazon and Alphabet again. That fits the narrative most people expect from a billionaire macro investor. What surprised me was that his single biggest holding was neither of those giants nor Nvidia. It was a genetic testing company called Natera (NTRA -0.97%).

That tells me something important. When a guy with Druckenmiller's track record makes a company almost one-fifth of his portfolio, I pay attention to what that business does and why it might be worth that kind of conviction. So instead of asking why he owns more Amazon, I find myself asking why he is willing to let a mid-cap diagnostics stock sit at the top of the stack.

Today's Change

(

-0.97

%) $

-3.23

Current Price

$

328.80

What is Natera? Natera is not a household consumer brand. It is a molecular diagnostics company focused on cell-free DNA testing. In plain language, it analyzes tiny fragments of DNA circulating in blood to answer questions about pregnancy, cancer, and organ health.

Its three main franchises are women's health, oncology, and transplant surveillance. Panorama screens for genetic conditions in unborn babies, Horizon checks parents for carrier status, Signatera tracks cancer recurrence, and Prospera monitors transplant rejection.

Stanley Druckenmiller, Duquesne Family Office Chairman. Image source: Getty Images.

What customers actually buy is not a kit like the one you might get at a pharmacy. They buy a test result. A sample goes to Natera's labs, their algorithms and lab workflow process it, and a report goes back to the doctor. Revenue mostly comes from per-test reimbursement, paid by Medicare, private insurers, and health systems. Oncology and transplant programs also generate revenue through biopharma partnerships and companion diagnostics.

For Druckenmiller, this does not look like a sleepy lab business. Natera's growth is real. In Q1 2026, total revenue reached about $696.6 million, up nearly 39% year over year. Oncology volumes jumped 54%, and the company processed over one million tests in a single quarter for the first time in its history. In Q2 2026, revenue climbed again to $752.8 million with gross margin around 64.5%. Natera processed about 1,043,900 tests, including almost 297,000 oncology tests, and raised full-year guidance to a range of $2.85 billion to $2.91 billion in revenue. Management now expects cash flow to be positive for the year.

Today's Change

(

1.62

%) $

5.55

Current Price

$

347.30

Signatera is the X-factor Under the hood, Signatera is the piece that keeps catching my eye. This is Natera's personalized molecular residual disease test, built to detect tiny traces of cancer DNA left after treatment or surgery. Natera has trained AI models on data from more than 300,000 patients tested with Signatera, integrating longitudinal blood results, digital pathology, and tumor sequencing.

That data helps refine risk scores and treatment decisions in ways standard imaging cannot. The company has secured the first FDA-approved companion diagnostic for blood-based MRD, the first PMDA-approved MRD test in Japan, and the first EU IVDR-certified personalized MRD test for solid tumors, along with a top-tier guideline recommendation for bladder cancer.

To me, that is the outline of a platform, not a single product. Every new cancer indication, every new guideline, and every new partnership adds another layer to a data asset that is hard to replicate. Of course, this is still biotech. Natera spends heavily on sales and research. For 2026, the company expects selling, general, and administrative expenses of around $1.1 billion to $1.2 billion and research and development expenses of around $800 million to $900 million. Regulatory risk, reimbursement changes, and competition all matter. The stock has already run a lot, which raises valuation questions.

That is why I do not read his Natera bet as a simple recommendation to pile in blindly. What I take from it is a view that the next decade of healthcare will include much more personalized, blood-based testing, and that owning a leader in cell-free DNA and MRD could be as important as owning a leader in AI chips. Druckenmiller can buy Amazon, Alphabet, and semiconductors like everyone else. The fact that he lets Natera sit at the top of his portfolio says he thinks this kind of diagnostics platform has a shot at becoming a core part of how medicine works.

Shares of Natera, Inc. (NASDAQ: NTRA - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-two analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have given a buy rating and two have

Key Takeaways Natera is supporting Kupando's Phase 1 skin cancer trial with its Latitude tissue-free MRD test.Latitude will track ctDNA at multiple timepoints to assess molecular response to KUP-101 treatment.The trial will enroll patients with advanced skin cancers at activated clinical sites in Germany. Natera (NTRA - Free Report) recently announced a collaboration with Kupando Therapeutics to support a Phase 1 clinical trial evaluating circulating tumor DNA (ctDNA) dynamics in patients with advanced skin cancers. The collaboration will use Natera’s Latitude tissue-free molecular residual disease (MRD) test to monitor treatment response to KUP-101, Kupando’s investigational immunotherapy targeting innate immune activation.

Management stated that Natera is pleased to support Kupando’s development of its first-in-class approach to innate immune activation. Latitude’s ability to evaluate ctDNA dynamics across diverse solid tumors can provide molecular insights into treatment response, potentially supporting the clinical development of KUP-101 in difficult-to-treat cancers.

Likely Trend of NTRA Stock Following the NewsShares of NTRA have declined 1.9% since the announcement on Wednesday. Year to date, shares of the company have gained 35.3% compared with the industry’s 0.6% growth and the S&P 500’s 13.2% rise.

The collaboration with Kupando Therapeutics could positively impact Natera by expanding the use of its Latitude MRD testing in early-stage clinical research. Incorporating Latitude into a Phase I trial provides an opportunity to demonstrate the assay’s ability to track ctDNA dynamics across multiple advanced skin cancers and potentially broader solid tumor types. Successful results could strengthen Natera’s position in the growing MRD and precision oncology market, support additional biopharma partnerships, and increase adoption of its testing platform in clinical trials.

NTRA currently has a market capitalization of $44.67 billion.

Image Source: Zacks Investment Research

More on the NewsThe collaboration follows the successful dosing of the first patient in Kupando’s Phase 1 trial. Following the initial dosing, Kupando’s safety committee approved continued enrollment across activated clinical sites, including leading oncology centers in Germany. The trial will generate serial molecular data to help characterize patient response to KUP-101 during treatment.

Under the collaboration, Latitude testing will be conducted at multiple timepoints during the trial to evaluate changes in ctDNA following KUP-101 treatment. The study is being conducted at activated clinical sites in Germany and will enroll patients with advanced tumors across multiple skin cancer types.

KUP-101 is designed to activate the innate immune system and induce trained immunity, offering a potentially tissue-agnostic approach across several solid tumor types. The investigational therapy is being evaluated both as a standalone treatment and in combination with other agents. By incorporating Latitude MRD testing into the trial, Kupando aims to better characterize the molecular activity of KUP-101 and generate data that may inform future clinical development.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the minimal residual disease testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.

Factors like the demand for highly sensitive technologies like next-generation sequencing and digital PCR, which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.

Other NewsNatera announced that its MRD test, Signatera, received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR) for use across multiple types of cancer. Signatera is certified to be used in adjuvant and surveillance settings across a broad range of cancers, including gastrointestinal, genitourinary, breast, skin, gynecological, head and neck, non-small cell lung cancer, diffuse large B-cell lymphoma, indolent non-Hodgkin's lymphomas and pan-cancer immunotherapy monitoring.

Natera partnered with Aveta Biomics to support AVTA 30-01, a global Phase 3 registrational trial of its oral immunotherapy, APG-157, in patients with locally advanced head and neck squamous cell carcinoma. Natera’s Signatera test will be integrated into the AVTA 30-01 Phase 3 study to assess MRD and treatment response during neoadjuvant, induction, adjuvant and follow-up care.

Natera partnered with Eledon Pharmaceuticals to integrate its Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed to prevent organ rejection in kidney transplantation.

NTRA’s Zacks Rank & Key PicksNatera currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

Empowered Funds LLC decreased its position in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 65.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,016 shares of the medical research company’s stock after selling 9,708 shares during the quarter. Empowered Funds LLC’s holdings in Natera were worth $1,003,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in NTRA. Reflection Asset Management purchased a new stake in Natera during the 4th quarter valued at $29,000. Palladiem LLC purchased a new stake in shares of Natera during the 4th quarter valued at about $31,000. Horizon Investments LLC purchased a new stake in shares of Natera during the 3rd quarter valued at about $32,000. International Assets Investment Management LLC grew its stake in shares of Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares during the period. Finally, Bank of Jackson Hole Trust grew its stake in shares of Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after acquiring an additional 83 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Price Performance NASDAQ:NTRA opened at $309.93 on Monday. Natera, Inc. has a one year low of $156.71 and a one year high of $326.03. The business has a fifty day moving average price of $263.76 and a 200-day moving average price of $226.30. The firm has a market capitalization of $44.67 billion, a price-to-earnings ratio of -227.89 and a beta of 1.51.

Natera (NASDAQ:NTRA – Get Free Report) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.Natera’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.74) earnings per share. On average, equities research analysts expect that Natera, Inc. will post -1.11 earnings per share for the current fiscal year. Analyst Upgrades and Downgrades A number of research analysts recently weighed in on NTRA shares. Robert W. Baird set a $348.00 price objective on shares of Natera in a research report on Friday, August 7th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Sanford C. Bernstein initiated coverage on Natera in a report on Friday, June 26th. They set an “outperform” rating and a $310.00 price target on the stock. Canaccord Genuity Group set a $375.00 price target on Natera in a research note on Friday, August 7th. Finally, Wells Fargo & Company lifted their price objective on Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $319.38.

View Our Latest Research Report on NTRA

Insider Activity In other Natera news, insider John Fesko sold 295 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $267.99, for a total transaction of $79,057.05. Following the sale, the insider owned 183,774 shares in the company, valued at approximately $49,249,594.26. This trade represents a 0.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,410 shares of Natera stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80. Following the transaction, the insider directly owned 129,019 shares in the company, valued at $34,264,866.02. This represents a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 181,045 shares of company stock valued at $41,330,968. 5.05% of the stock is owned by insiders.

Natera Company Profile (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Further Reading Five stocks we like better than Natera The Metals Company’s Big Bet Now Comes Down to a License OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings Meta and Tesla Are Rebounding From Oversold Levels—Now What? AMG’s Alternatives Boom Powers Record Growth Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Natera, Inc. (NTRA) Canaccord Genuity's 46th Annual Growth Conference August 12, 2026 12:00 PM EDT

Company Participants

Mike Brophy - Chief Financial Officer

Conference Call Participants

Kyle Mikson - Canaccord Genuity Corp., Research Division

Presentation

Kyle Mikson
Canaccord Genuity Corp., Research Division

Welcome to the Canaccord Genuity Growth Conference. I'm Kyle Mikson. I cover life science tools and diagnostics with Canaccord. Pleased to have Natera here with us for a fireside chat. With the company, we have Mike Brophy, CFO. And just for background, Natera is a leading provider of cell-free DNA-based testing for women's health oncology, and organ health.

So thanks all for joining us. Appreciate it.

Mike Brophy
Chief Financial Officer

Thanks for having me.

Question-and-Answer Session

Kyle Mikson
Canaccord Genuity Corp., Research Division

Let's start with the second quarter results you guys announced last week. It was -- I think you beat by like $100 million or so, raised the guidance. Just walk through the puts and takes of the quarter, and then we'll get into some specifics.

Mike Brophy
Chief Financial Officer

Yes, had a fantastic Q2, just read it out last week. Outstanding volume quarter across the board, very strong momentum in organ health and had an outstanding Q2 in women's health, which is sequentially seasonally down for us usually. And then sequentially, we were really strong. And that was, kind of, high single-digit growth year-on-year, which is quite difficult to achieve in such a penetrated market. But nonetheless, we got there.

Probably the headline for the quarter, I think, from investors' perspective was the growth that we posted in Signatera, which just sequential to a very strong Q1 of this year, we grew an additional 34,000 units to now north of 280,000 units in the quarter. That's a record for us. The prior quarter was also a record at 25,000. So that's

Matthew Rabinowitz, the executive chairman of Natera, Inc. (NTRA -1.16%), sold 731 shares of common stock at $267.99 per share on August 3, according to an SEC Form 4 filing.

Transaction summaryMetricValueShares sold (directly held)731Transaction value$195,901Post-transaction shares (directly held)2,275,394Post-transaction shares (indirectly held)4,000Post-transaction value$616.26 millionTransaction value based on SEC Form 4 weighted average sale price ($267.99); post-transaction value based on the August 3 market close ($270.36).

Key questionsWhat was the motivation for this disposition?
The sale was non-discretionary and performed specifically to satisfy tax withholding and remittance obligations triggered by the vesting of restricted stock units. This arrangement was established under a Rule 10b5-1(c) plan dated January 31, 2025, and does not reflect a discretionary change in the executive's investment thesis.How significant is the remaining equity position?
Matthew Rabinowitz continues to hold a substantial interest in the company, with roughly 2.3 million shares held directly and an additional 4,000 shares held indirectly through a spouse. This total beneficial ownership is valued at approximately $616.26 million as of the August 3 market close.What is the recent performance context for the stock?
As of the August 3 transaction date, Natera had delivered a one-year total return of roughly 100%. The stock was priced at $275.19 as of the August 4 market close, representing a market capitalization of $39.4 billion.Company OverviewMetricValueShare Price (as of market close 2026-08-04)$275.19Market Capitalization$39.4 billionRevenue (TTM)$2.7 billionNet Income (TTM)-$192.3 millionCompany SnapshotNatera develops and commercializes a comprehensive portfolio of molecular diagnostic testing services, including Panorama (non-invasive prenatal testing), Vistara (single-gene disorder screening), and Horizon (carrier screening), generating revenue through direct laboratory testing services and licensing arrangements.The company operates a laboratory services business model, processing patient samples and delivering diagnostic results to healthcare providers and patients, with revenue derived from test volumes, per-test pricing, and reimbursement from insurance carriers and government programs.Natera serves obstetricians, gynecologists, reproductive endocrinologists, and genetic counselors as primary customers, while targeting expectant parents and individuals seeking genetic risk assessment across prenatal, carrier, and hereditary cancer screening markets.Natera is a leading molecular diagnostics company with a market capitalization of $39.4 billion and TTM revenue of $2.7 billion, positioning it among the largest players in the genetic testing sector. The company has achieved substantial scale and maintains a diversified test portfolio addressing multiple clinical indications across reproductive health and hereditary disease screening. Despite current net losses, Natera's strong revenue growth trajectory and commanding market position reflect investor confidence in the expanding demand for non-invasive genetic testing solutions.

What this transaction means for investorsSet against what he owns, this sale rounds to nothing. Rabinowitz sold 731 shares while holding roughly $616 million of Natera stock, so the fraction that left to cover a tax bill is a rounding error on a co-founder's fortune — which is a billionaire-level fortune in this case, according to Forbes. The shares vested and were withheld automatically under a plan set in early 2025, which is about as far from a discretionary call as an insider filing gets. He sold on August 3, days before the company reported, so the timing predates the news that moved the stock.

That report was a strong one. Natera grew second-quarter revenue about 38% to $753 million, beat expectations handily, and raised its full-year outlook, driven by its Signatera cancer test, whose clinical volume climbed 56%. Gross margin reached about 65%, up on better pricing and efficiency. So what’s the verdict for long-term investors? A co-founder parting with a few hundred shares to satisfy taxes, days before a quarter like that, really tells you nothing except that the calendar and the tax code did their usual work. More importantly, the firm is firing on all cylinders, and momentum is on its side.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Natera. The Motley Fool has a disclosure policy.

Solomon Moshkevich, president of clinical diagnostics at Natera, Inc. (NTRA -1.16%), sold 3,410 shares of common stock on August 3, according to an SEC Form 4 filing.

Transaction summaryMetricValueTransaction value$906,000Shares sold3,410Post-transaction shares (directly held)129,000Post-transaction value$34.88 millionTransaction value based on SEC Form 4 weighted average sale price ($265.58); post-transaction value based on the August 3 market close ($270.36).

Key questionsWhat was the primary driver of this transaction?
The disposition was non-discretionary, executed to cover tax withholding obligations related to the vesting of restricted stock units, and does not reflect the insider's view on the stock. The sale was conducted under a Rule 10b5-1 trading plan adopted on November 26, 2024, in accordance with written instructions dated January 31, 2025.How much equity does the insider retain in the company?
Following the sale, Solomon Moshkevich retains a direct interest of about 129,000 shares, representing a 0.09% ownership stake. This remaining position is valued at $34.88 million as of the August 3 market close.What is the recent market context for the stock?
Natera has seen an over 100%% one-year return as of the August 3 transaction date. As of the August 4 market close, shares were priced at $275.19. Company OverviewMetricValueShare Price (as of market close 2026-08-04)$275.19Market Capitalization$39.4 billionRevenue (TTM)$2.7 billionNet Income (TTM)-$192.3 millionCompany SnapshotNatera develops and commercializes a comprehensive portfolio of molecular diagnostic testing services, including Panorama (non-invasive prenatal testing), Vistara (single-gene disorder screening), and Horizon (carrier screening), generating revenue through direct laboratory testing services and licensing arrangements.The company operates a laboratory services business model, processing patient samples and delivering diagnostic results to healthcare providers and patients, with revenue derived from test volumes, pricing per test, and reimbursement from insurance carriers and government programs.Natera serves obstetricians, gynecologists, reproductive endocrinologists, and genetic counselors as primary customers, while targeting expectant parents and individuals seeking genetic risk assessment across prenatal, carrier, and hereditary cancer screening markets.Natera is a leading molecular diagnostics company with a market capitalization of $39.4 billion and TTM revenue of $2.7 billion, positioning it among the largest players in the genetic testing sector. The company has achieved substantial scale with a diversified test portfolio addressing multiple clinical indications across reproductive health and hereditary disease screening. Despite current net losses, Natera's strong revenue growth trajectory and commanding market position reflect investor confidence in the expanding demand for non-invasive genetic testing solutions.

What this transaction means for investorsMoshkevich runs the part of the company that actually powered the quarter, since clinical diagnostics is home to Signatera, the cancer test behind Natera's surge, and that makes his filing more interesting than many other others who filed reports this past week even though the sale itself is pure mechanics, essentially tax withheld on vesting shares under a plan set well in advance. He sold before earnings and kept a stake worth about $35 million, so nothing here signals doubt.

Meanwhile, the business delivered the quarter's standout numbers. Natera's molecular residual disease testing, the Signatera franchise, grew volume about 56% to 283,000 units, helping lift second-quarter revenue roughly 38% to $753 million and prompting a $100 million guidance raise. Signatera also picked up fresh regulatory wins in the period, including U.S. companion-diagnostic approval in bladder cancer to deepen its foothold in oncology. With shares more than doubling this past year and nearing records, the market is pricing in continued execution, which amounts to greater risk, but the firm certainly has momentum on its side.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Natera. The Motley Fool has a disclosure policy.

ToplineGenomics powerhouse Natera surged in trading Friday following a blowout second-quarter earnings report and a strong revenue beat, sending the stock to an all-time high and its co-founder’s billionaire fortune even higher.

Natera reported its second quarter earnings Friday.

Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images

Key FactsNatera shares closed up 21.3% at $322.10 on Friday, recording an all-time high and pushing co-founder Matthew Rabinowitz’s estimated net worth to at least $1.5 billion, according to the company's annual proxy filing and market data.

Friday’s surge in share price was fueled by what one analyst described as “blowout volume” for Natera’s cancer-detecting blood test Signatera in the second quarter, as the company reported $752.8 million in revenue, well above the estimate of $673.9 million, according to Finnhub earnings data.

Natera’s market capitalization jumped to $46.1 billion after ending July around $38 billion, according to market data.

Rabinowitz holds roughly 2.28 million shares worth approximately $717 million, as well as options and vesting restricted stock units, according to the company's proxy filing and insider transaction disclosures.

Big Number40.6%. That is how much Natera shares have grown since the start of the year, when they were priced around the $228 mark. The company’s lowest closing price this year occurred in late March, when shares fell to $182.65.

TangentRabinowitz also holds roughly 19.4% of genome firm MyOme on a fully diluted basis as of March 31, according to the proxy.

Key BackgroundRabinowitz was chief executive for a location-services technology company between 2000 and 2007 and co-founded Natera in 2005, working as chief executive for 14 years before becoming executive chairman. A Stanford University graduate, he also logged stints as a consulting professor at his alma mater from 2004 to 2012 and later worked in Harvard’s genetics department. His research spans over 100 patents and publications about subjects like bioinformatics, machine learning and genetic testing, which earned him IEEE's Scott Helt Memorial Award and the World Economic Forum's Technology Pioneer Award for two separate companies he founded. Natera appears to have benefited from his leadership, dramatically increasing testing volume and jumping from annual revenue in the low hundreds of millions to $2.3 billion within the last decade.

Natera (NTRA - Free Report) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.74 per share a year ago. These figures are adjusted for non-recurring items.

A quarter ago, it was expected that this genetic testing company would post a loss of $0.53 per share when it actually produced a loss of $0.56, delivering a surprise of -5.66%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Natera, which belongs to the Zacks Medical Services industry, posted revenues of $752.75 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 14.23%. This compares to year-ago revenues of $546.6 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Natera shares have added about 19.9% since the beginning of the year versus the S&P 500's gain of 12.8%.

What's Next for Natera?While Natera has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Natera was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.32 on $695.41 million in revenues for the coming quarter and -$1.52 on $2.8 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Lifeward (LFWD - Free Report) , is yet to report results for the quarter ended June 2026.

This maker of wearable robotic exoskeletons that help paralyzed patients walk is expected to post quarterly loss of $1.49 per share in its upcoming report, which represents a year-over-year change of +78.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Lifeward's revenues are expected to be $7.42 million, up 29.7% from the year-ago quarter.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2026.

Recent Financial Highlights

Generated total revenues of $752.8 million in the second quarter of 2026, compared to $546.6 million in the second quarter of 2025, an increase of 37.7%. Generated a gross margin1 of 64.5% in the second quarter of 2026, compared to a gross margin1 of 63.4% in the second quarter of 2025. Excluding revenue true-ups, second quarter non-GAAP gross margin2 improved 50 basis points over the first quarter of 2026. Processed approximately 1,043,900 tests in the second quarter of 2026, compared to approximately 853,100 tests in the second quarter of 2025, an increase of 22.4%. Processed approximately 296,700 oncology tests in the second quarter of 2026, compared to approximately 188,800 in the second quarter of 2025, an increase of 57.2%. Clinical molecular residual disease (MRD) oncology units grew 34,000 units over the first quarter of 2026, the largest sequential increase to-date. Increased cash by approximately $3.6 million3 during the second quarter of 2026. Raised 2026 annual revenue guidance by $100 million at the midpoint, from $2.74 billion - $2.82 billion to $2.85 billion - $2.91 billion. “We had an exceptional quarter helping patients, with over one million tests processed for the second consecutive quarter and record growth in oncology volumes,” said Steve Chapman, chief executive officer of Natera. “We also reached several landmark milestones in the last few months: SignateraTM achieved three significant regulatory approvals, Medicare coverage expanded for ProsperaTM, and we launched a major enhancement to our PanoramaTM NIPT.”

Second Quarter Ended June 30, 2026 Financial Results

Total revenues were $752.8 million in the second quarter of 2026 compared to $546.6 million in the second quarter of 2025, an increase of 37.7%. The increase in revenues was driven by an increase in volume and average selling price improvements.

Natera processed approximately 1,043,900 tests in the second quarter of 2026, including approximately 1,030,100 tests accessioned in its laboratory, compared to approximately 853,100 tests processed, including approximately 839,300 tests accessioned in its laboratory, in the second quarter of 2025.

In the second quarter of 2026, Natera recognized revenue on approximately 985,500 tests for which results were reported to customers in the period (tests reported), including approximately 972,000 tests reported from its laboratory, compared to approximately 812,900 tests reported, including approximately 799,900 tests reported from its laboratory, in the second quarter of 2025, an increase of 21.2% from the prior period.

Gross profit1 for the three months ended June 30, 2026 and 2025 was $485.2 million and $346.6 million, respectively, representing a gross margin1 of 64.5% and 63.4%, respectively. Natera had higher gross margin1 in the second quarter of 2026 primarily as a result of higher revenues and continued progress in reducing cost of revenues associated with tests processed. There was also a change in estimate of approximately $52.3 million in the second quarter of 2026 in revenue accrual as compared to $45.3 million in the second quarter of 2025. Changes in estimates for the three months ended June 30, 2026 and 2025 increased revenue and, as a result, increased gross margin1 and gross profit1 by 2.7% and $52.3 million, and by 3.3% and $45.3 million, respectively.

Gross margin1 for the three months ended March 31, 2026 was 64.7%. Excluding the change in estimates in revenue accruals of approximately $52.3 million and $61.0 million during the three months ended June 30, 2026 and March 31, 2026, respectively, Natera’s non-GAAP gross margin2 increased by approximately 0.5% sequentially.

Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the second quarter of 2026 was $555.3 million, compared to $457.0 million in the same period of the prior year, an increase of 21.5%. The increase was primarily driven by headcount growth to support new product offerings as well as increases in clinical trial expenses. Amortization of acquired intangible assets for the second quarter of 2026 was $5.7 million. No such amortization occurred in the second quarter of 2025.

Loss from operations for the second quarter of 2026 was $75.8 million compared to $110.4 million for the same period of the prior year.

Natera’s net loss for the second quarter of 2026 was $67.0 million, or ($0.47) per diluted share, compared to a net loss of $100.9 million, or ($0.74) per diluted share, in the second quarter of 2025. Weighted average shares outstanding were 143.3 million in the second quarter of 2026 compared to 136.4 million for the same period in the prior year.

At June 30, 2026, Natera held approximately $1,091.5 million in cash, cash equivalents, and restricted cash, compared to $1,076.1 million as of December 31, 2025. As of June 30, 2026, Natera had a total outstanding debt balance of $80.3 million including accrued interest under its line of credit with UBS at a variable interest rate of 30-day SOFR plus 50 bps.

Financial Outlook

Natera anticipates 2026 total revenue of $2.85 billion to $2.91 billion; 2026 gross margin1 to be approximately 64% to 66%; selling, general and administrative costs to be approximately $1.125 billion to $1.225 billion; research and development costs to be $800 million to $900 million; and cash flow to be positive.

Test Volume Summary

Unit

QTD 2026

QTD 2025

Definition

Tests processed

1,043,900

853,100

Tests accessioned in our laboratory plus units processed outside of our laboratory

Tests accessioned

1,030,100

839,300

Test accessioned in our laboratory

Tests reported

985,500

812,900

Total tests reported

Tests reported in our laboratory

972,000

799,900

Total tests reported in our laboratory less units reported outside of our laboratory

About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Conference Call Information

Event:

Natera’s Second Quarter Financial Results Conference Call

Date:

Thursday, August 6, 2026

Time:

1:30 p.m. PT (4:30 p.m. ET)

Live Dial-In:

1-833-461-5787 (Domestic)
+44-808-196-8935 (International)

Conference ID:

786 717 759

Webcast Link:

https://events.q4inc.com/attendee/786717759

Forward-Looking Statements

This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our market opportunity, anticipated products and launch schedules, reimbursement coverage, product costs, and gross margins, commercial and strategic partnerships and acquisitions, user experience, clinical trials and studies, and our strategies, goals and general business and market conditions, are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera’s current plans, estimates, and expectations, as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved.

These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to further increase the use and adoption of our products through our direct sales efforts or through our laboratory partners; we have incurred net losses since our inception and we anticipate that we will continue to incur net losses for the foreseeable future; our quarterly results may fluctuate from period to period; unless otherwise indicated, all financial data for the current and prior quarters are unaudited and subject to adjustment in connection with the completion of our quarterly and annual financial reporting processes; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may engage in acquisitions, dispositions or other strategic transactions that may not achieve our anticipated benefits and could otherwise disrupt our business, cause dilution to our stockholders or reduce our financial resources; our products may not perform as expected; the results of our clinical studies may not support the use and reimbursement of our tests, particularly for microdeletions screening, and may not be able to be replicated in later studies required for regulatory approvals or clearances; if either of our primary CLIA-certified laboratories becomes inoperable, we will be unable to perform our tests and our business may be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand, obtain or maintain third-party payer coverage and reimbursement for our tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors; we could incur substantial costs and delays complying with governmental regulations; litigation and other regulatory or governmental proceedings related to our intellectual property or the commercialization of our tests, are costly, time-consuming, could result in our obligation to pay material judgments or incur material settlement costs, and could limit our ability to commercialize our tests; and any inability to effectively protect our proprietary technology could harm our competitive position or our brand.

We discuss these and other risks and uncertainties in greater detail in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our periodic reports on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time. These documents are available on our website at www.natera.com under the Investor Relations section and on the SEC’s website at www.sec.gov.

We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, you should not place undue reliance on our forward-looking statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations.

References:

Gross profit is calculated as GAAP total revenues less GAAP cost of revenues. Gross margin is calculated as gross profit divided by GAAP total revenues. Excluding the change in estimates in revenue accruals of approximately $52.3 million and $61.0 million during the three months ended June 30, 2026 and March 31, 2026, respectively, Natera’s non-GAAP gross margin increased by approximately 0.5% sequentially. Includes GAAP cash, cash equivalents and restricted cash. Natera, Inc.

Consolidated Balance Sheets

(Unaudited)

(in thousands, except shares)

  June 30,
2026

December 31,
2025

(1)

Assets

Current assets:

Cash, cash equivalents and restricted cash

$

1,091,502

$

1,076,140

Accounts receivable, net of allowance of $6,526 in 2026 and $8,018 in 2025

421,968

296,528

Inventory

80,346

68,443

Prepaid expenses and other current assets

65,134

55,828

Total current assets

1,658,950

1,496,939

Property and equipment, net

317,568

241,184

Operating lease right-of-use assets

129,687

108,541

Goodwill

141,100

141,070

Intangible assets

360,204

373,713

Other assets

49,988

36,897

Total assets

$

2,657,497

$

2,398,344

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

75,154

$

33,156

Accrued compensation

105,915

92,603

Contingent consideration payable, current portion

22,818

21,580

Deferred revenue, current portion

40,566

24,907

Short-term debt financing

80,291

80,323

Other accrued liabilities

228,456

188,659

Total current liabilities

553,200

441,228

Contingent consideration payable, long-term portion

97,687

96,780

Deferred tax liability, long-term portion

701

701

Operating lease liabilities, long-term portion

143,074

118,473

Deferred revenue, long-term portion

16,074

17,062

Other liabilities

25,262

11,687

Total liabilities

835,998

685,931

Commitments and contingencies

Stockholders’ equity:

Common stock (2)

14

14

Additional paid in capital

4,749,675

4,488,679

Accumulated deficit

(2,928,082

)

(2,776,022

)

Accumulated other comprehensive loss

(108

)

(258

)

Total stockholders’ equity

1,821,499

1,712,413

Total liabilities and stockholders’ equity

$

2,657,497

$

2,398,344

Natera, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except per share data)

  Three months ended
June 30,

Six months ended
June 30,

2026

2025

2026

2025

Revenues

Product revenues

$

747,929

$

544,427

$

1,441,796

$

1,044,463

Licensing and other revenues

4,821

2,173

7,598

3,968

Total revenues

752,750

546,600

1,449,394

1,048,431

Cost and expenses

Cost of product revenues

266,597

199,531

511,800

384,143

Cost of licensing and other revenues

964

465

1,572

917

Research and development

228,071

146,427

438,773

275,504

Selling, general and administrative

327,203

310,549

655,142

577,414

Amortization of acquired intangible assets

5,707

—

11,416

—

Total cost and expenses

828,542

656,972

1,618,703

1,237,978

Loss from operations

(75,792

)

(110,372

)

(169,309

)

(189,547

)

Interest expense

(890

)

(1,029

)

(1,782

)

(2,034

)

Interest and other income, net

9,452

10,738

19,053

24,155

Loss before income taxes

(67,230

)

(100,663

)

(152,038

)

(167,426

)

Income tax benefit (expense)

261

(275

)

(22

)

(448

)

Net loss

$

(66,969

)

$

(100,938

)

$

(152,060

)

$

(167,874

)

Unrealized gain (loss) on available-for-sale securities and foreign currency translation adjustment

94

(90

)

150

57

Comprehensive loss

$

(66,875

)

$

(101,028

)

$

(151,910

)

$

(167,817

)

Net loss per share:

Basic and diluted

$

(0.47

)

$

(0.74

)

$

(1.07

)

$

(1.24

)

Weighted-average number of shares used in computing basic and diluted net loss per share:

Basic and diluted

143,279

136,388

142,395

135,632

  More News From Natera, Inc.

-

Follows Signatera’s recent U.S. FDA approval in MIBC and Japanese PMDA approval in CRC

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of the Signatera test in muscle-invasive bladder cancer (MIBC) as a companion diagnostic (CDx).

The submission advances Natera’s growing presence in Japan, where Signatera received PMDA approval in colorectal cancer in June, becoming the country’s first PMDA-approved molecular residual disease (MRD) test.

The MIBC application is supported by data from IMvigor011, a randomized, double-blind Phase 3 clinical trial. It also builds on recent milestones for Signatera in MIBC: the U.S. FDA’s approval of Signatera™ CDx as a companion diagnostic for adjuvant atezolizumab (Tecentriq®); and a Category 1 recommendation for Signatera MRD-guided adjuvant atezolizumab in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for Bladder Cancer.

Bladder cancer affects more than 34,000 people in Japan each year.1 Globally, approximately 20–25% of newly diagnosed bladder cancers are muscle-invasive.2 MIBC is a more aggressive form of the disease, associated with higher recurrence risk and treatment complexity.

“Signatera is a proven tool in bladder cancer management, and this submission reflects our commitment to bringing precision diagnostics to patients in Japan,” said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera. “We look forward to engaging with the PMDA and to improving outcomes for patients around the world.”

Notes

Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.

References

World Cancer Research Fund International. Bladder cancer statistics. Accessed June 26, 2026. https://www.wcrf.org/preventing-cancer/cancer-statistics/bladder-cancer-statistics/ Gakis G. Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives. Eur. Urol. Focus. 2020;6(4):632-638. About Natera

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

More News From Natera, Inc.

Back to Newsroom

Posted by Defense World Staff on Jul 25th, 2026

Arrowstreet Capital Limited Partnership raised its position in Natera, Inc. (NASDAQ:NTRA – Free Report) by 1.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,191,732 shares of the medical research company’s stock after purchasing an additional 11,793 shares during the quarter. Arrowstreet Capital Limited Partnership owned about 0.83% of Natera worth $238,334,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Reflection Asset Management purchased a new position in shares of Natera during the 4th quarter worth $29,000. Palladiem LLC purchased a new stake in Natera in the 4th quarter valued at about $31,000. Bank of Jackson Hole Trust raised its holdings in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after buying an additional 83 shares during the period. International Assets Investment Management LLC lifted its position in Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after buying an additional 97 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Natera in the 4th quarter valued at approximately $39,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes A number of research firms recently weighed in on NTRA. Wolfe Research initiated coverage on shares of Natera in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective for the company. Barclays cut their target price on Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 24th. Guggenheim raised their target price on Natera from $270.00 to $290.00 and gave the company a “buy” rating in a report on Monday, June 29th. Evercore reissued an “outperform” rating and set a $300.00 price target on shares of Natera in a research report on Monday, July 6th. Finally, Zacks Research downgraded shares of Natera from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $267.83.

Get Our Latest Report on NTRA

Natera Stock Performance NASDAQ:NTRA opened at $261.99 on Friday. The stock has a 50-day simple moving average of $240.75 and a 200-day simple moving average of $221.61. The stock has a market cap of $37.52 billion, a P/E ratio of -160.73 and a beta of 1.51. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $288.04.

Insider Activity at Natera In related news, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $272.90, for a total transaction of $818,700.00. Following the sale, the insider directly owned 134,643 shares in the company, valued at $36,744,074.70. This trade represents a 2.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Herm Rosenman sold 16,530 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the completion of the sale, the director directly owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. This trade represents a 79.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,872 shares of company stock valued at $39,627,696 in the last quarter. Company insiders own 5.05% of the company’s stock.

Natera Company Profile (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Featured Articles Five stocks we like better than Natera AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Plugging In: How Kinder Morgan Powers Up Profits

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of New York Mellon Corp Has $44.25 Million Holdings in SS&C Technologies Holdings, Inc. $SSNC

NEXT HEADLINE »Affinity Asset Advisors LLC Buys Shares of 250,000 Spyglass Pharma, Inc. $SGP

Posted by Defense World Staff on Jul 22nd, 2026

Fifth Third Bancorp boosted its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 3,373.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,253 shares of the medical research company’s stock after purchasing an additional 10,929 shares during the period. Fifth Third Bancorp’s holdings in Natera were worth $2,251,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Coatue Management LLC lifted its stake in Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after acquiring an additional 2,463,008 shares during the period. Wellington Management Group LLP raised its holdings in Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares in the last quarter. Norges Bank bought a new position in Natera in the 4th quarter worth $372,398,000. JPMorgan Chase & Co. lifted its position in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after purchasing an additional 1,225,420 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of Natera by 39.0% in the 3rd quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock worth $386,338,000 after purchasing an additional 673,315 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Activity In related news, Director Roelof Botha sold 78,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the sale, the director directly owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. This represents a 6.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 3,405 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45. Following the sale, the insider owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. This represents a 2.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 178,872 shares of company stock valued at $39,627,696. 5.05% of the stock is currently owned by insiders.

Natera Stock Up 1.7% NTRA stock opened at $267.18 on Wednesday. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $288.04. The firm has a market cap of $38.26 billion, a PE ratio of -163.91 and a beta of 1.51. The business has a 50 day moving average of $236.50 and a 200 day moving average of $220.83.

Wall Street Analyst Weigh In Several equities analysts recently issued reports on the stock. Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Canaccord Genuity Group lifted their price objective on Natera from $285.00 to $330.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Evercore reiterated an “outperform” rating and set a $300.00 target price on shares of Natera in a report on Monday, July 6th. BTIG Research set a $275.00 target price on shares of Natera and gave the company a “buy” rating in a report on Wednesday, June 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Friday. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $267.83.

Get Our Latest Report on Natera

About Natera (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Read More Five stocks we like better than Natera Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of New York Mellon Corp Sells 117,297 Shares of Booz Allen Hamilton Holding Corporation $BAH

NEXT HEADLINE »Domino’s Pizza Inc $DPZ Position Reduced by Bank of New York Mellon Corp

-

Signatera outperformed AMERK, the current standard of care for prognosis and recurrence monitoring, across sensitivity, positive and negative predictive value, and lead time to recurrence

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) published in JAMA Dermatology. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected relapse earlier.

MCC is a rare but aggressive skin cancer that recurs in approximately 40% of patients.1 Despite its severity, clinicians have lacked a reliable, universal biomarker to guide surveillance. The AMERK test has been a widely used monitoring tool, but its utility is limited: it can only be used in the roughly 50% of MCC patients whose tumors are virus-positive, and its accuracy diminishes after immunotherapy exposure or multiple recurrences.2-3 Signatera’s clinical validation has been published across all MCC patients, irrespective of viral status, leading to inclusion in NCCN Guidelines as a recommendation for surveillance monitoring.

This published study is a retrospective analysis of a prospective, multicenter, head-to-head comparison of Signatera and AMERK testing in 169 patients with MCC. Key findings include:

Superior predictive power: The Signatera test was a significantly stronger predictor of recurrence than AMERK (HR difference = 6.6; p < 0.001), with higher hazard ratios, higher positive predictive value (PPV), and higher negative predictive value (NPV).Higher Sensitivity: Signatera detected recurrence more frequently than AMERK with a sensitivity of 90% vs 55%, respectively.Longer Lead Time: In patients where recurrence was detected by both tests, Signatera detected recurrence earlier than AMERK with a median lead time of 5.1 months vs. 2.1 months, respectively.“For years, AMERK had been our best available tool, but its inability to function in virus-negative patients and after immunotherapy has been a recognized limitation,” said Lisa Zaba, M.D., Ph.D., associate professor of dermatology and director of the Merkel cell carcinoma multidisciplinary clinic at the Stanford University School of Medicine, and corresponding author of the study. “These data demonstrate that Signatera can give clinicians a more precise and earlier signal across all patients, enabling more proactive management of this challenging disease.”

“Signatera MRD testing outperformed AMERK across every key measure in this study — sensitivity, hazard ratios, predictive values, and lead time to detection,” said Alexey Aleshin, M.D., MBA, corporate chief medical officer and general manager, oncology, at Natera. “Signatera was shown to be a more universally reliable biomarker for MCC surveillance, particularly because it retains its accuracy in both virus-positive and virus-negative disease and after exposure to immunotherapy.”

References

McEvoy AM, Lachance K, Hippe DS, et al. Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis. JAMA Dermatol. 2022;158(4):382-389. doi:10.1001/jamadermatol.2021.6096Paulson KG, Lewis CW, Redman MW, et al. Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: a prospective validation study. Cancer. 2017;123(8):1464-1474. doi:10.1002/cncr.30475Miller DM, Shalhout SZ, Wright KM, et al. The prognostic value of the Merkel cell polyomavirus serum antibody test: a dual institutional observational study. Cancer. 2024;130(15):2670-2682. doi:10.1002/cncr.35314About Natera

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

More News From Natera, Inc.

Back to Newsroom

Posted by Defense World Staff on Jul 18th, 2026

Allspring Global Investments Holdings LLC grew its holdings in Natera, Inc. (NASDAQ:NTRA – Free Report) by 2.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 463,477 shares of the medical research company’s stock after purchasing an additional 8,979 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.33% of Natera worth $94,183,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the business. Reflection Asset Management acquired a new stake in Natera in the fourth quarter worth $29,000. Palladiem LLC acquired a new position in shares of Natera during the fourth quarter worth approximately $31,000. Bank of Jackson Hole Trust lifted its holdings in shares of Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after purchasing an additional 97 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in Natera in the 4th quarter valued at $39,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Price Performance NASDAQ:NTRA opened at $271.39 on Friday. The company has a market capitalization of $38.87 billion, a price-to-earnings ratio of -166.50 and a beta of 1.51. The business has a 50 day moving average of $233.97 and a 200 day moving average of $220.41. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $288.04.

Insider Buying and Selling at Natera In related news, Director Herm Rosenman sold 16,530 shares of Natera stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the sale, the director owned 4,250 shares in the company, valued at $1,062,500. The trade was a 79.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the transaction, the director owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This trade represents a 64.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 178,872 shares of company stock worth $39,627,696 over the last three months. 5.05% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In NTRA has been the subject of a number of analyst reports. UBS Group set a $260.00 price target on Natera in a research note on Wednesday, June 24th. Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Guggenheim upped their target price on shares of Natera from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Canaccord Genuity Group increased their target price on shares of Natera from $285.00 to $330.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wells Fargo & Company increased their price objective on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus price target of $267.83.

Read Our Latest Stock Analysis on Natera

Natera Profile (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

See Also Five stocks we like better than Natera AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident GE Aerospace Faces a Prove-It Moment in Q2 Earnings

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEEagle Eye Solutions Group (LON:EYE) Given House Stock Rating at Shore Capital Group

NEXT HEADLINE »Allspring Global Investments Holdings LLC Increases Stock Position in iShares MSCI Brazil ETF $EWZ

He's a retired hedge fund manager, but people still want to know what billionaire Stanley Druckenmiller is doing with his money. The answer? Investing in the medical diagnostic company Natera (NTRA 0.31%).

As of the first quarter of 2026, Natera was the top holding of the Duquesne Family Office, which manages Druckenmiller's private wealth. It accounted for 18.1% of the portfolio's holdings, and the stake was worth slightly under $613 million at the time.

The genetic testing company may not be as well known as Nvidia or get as much attention, but surprisingly, Natera has quietly returned three times more than the chipmaker over the past 12 months.

Stanley Druckenmiller. Image source: Getty Images.

Druckenmiller keeps betting big on Natera Duquesne provides quarterly filings showing what it bought and sold, but it isn't required to explain its investment decisions.

Still, as the medical testing market is rapidly growing, it makes sense as to why Druckenmiller and his family office have been aggressively building a position in Natera. According to Grand View Research, the global genetic testing market was valued at only $11.7 billion in 2024, but is expected to reach $39.3 billion by 2030. And the global cancer diagnostics market is even bigger, expected to climb from $119.8 billion in 2025 to $191.1 billion by 2033.

Natera has a lot of opportunities within those markets, as it specializes in cell-free DNA testing and has testing for oncology, organ health, and women's health. It also offers testing for rare diseases. One product growth source for the company, in particular, has been through oncology testing. Last year, Natera increased its processed oncology tests by 51.6% from over 528,000 in 2024 to more than 800,000 in 2025. In the first quarter of 2026, it also saw a 50%+ increase in processed oncology tests.

In addition, Natera offered its shareholders even more bullish news in June, as its Signatera test became the first approved molecular residual disease test approved for patients with colorectal cancer in Japan. Signatera is expected to launch in Japan by the end of 2026.

Strong results continue into 2026 In 2025, Natera generated $2.3 billion, which was a 35.9% increase from 2024. That's on the back of increased testing; Natera processed 3.5 million total tests in 2025, a 15% increase from the number of tests processed in 2024.

Thus far, Natera is continuing to ride that wave of momentum. In the first quarter of 2026, it exceeded one million processed tests in a quarter for the first time. It also reported revenue of $697 million, a 39% increase, and Natera also boosted the midpoint of its full-year sales guidance by $120 million.

Today's Change

(

-0.31

%) $

-0.87

Current Price

$

276.50

Should you follow Druckenmiller's lead into Natera? Natera continues to show that demand for its testing is increasing, and shareholders have been rewarded with a rising stock price. As of this writing, the Natera stock price is up over 19%, and while it may not make investing headlines like Nvidia, Natera is performing better than the chipmaker. Over the last 12 months, the Natera stock price has been up more than 72%, while the Nvidia stock price has climbed slightly above 24%.

It's also a company that analysts generally view favorably, with 19 out of 22 saying Natera is a buy.

That said, Natera is also an unprofitable company. In 2025, it reported a net loss of $208.2 million, up from a net loss of $190.4 million in 2024. It's also continuing to invest heavily in research and development (R&D), with its R&D costs climbing from $129.1 million in Q1 2025 to $210.7 million in Q1 2026.

Overall, Natera can reward shareholders who are comfortable with an investment with high-reward potential but also increased risk. It's a leader in the medical diagnostics space and continues to report impressive revenue growth.

But owning Natera also means accepting the company's unprofitability, which may continue for some time. Druckenmiller appears comfortable with the risk associated with his Natera investment, but that's not reason alone for retail investors to own the stock.

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter.

Life and the stock market are both about expectations, and rising above what is expected is often rewarded, while falling short can come with negative consequences. Investors might want to try to capture stronger returns by finding positive earnings surprises.

The ability to identify stocks that are likely to top quarterly earnings expectations can be profitable, but it's no simple task. Here at Zacks, our Earnings ESP filter helps make things easier.

The Zacks Earnings ESP, ExplainedThe Zacks Earnings ESP, or Expected Surprise Prediction, aims to find earnings surprises by focusing on the most recent analyst revisions. The basic premise is that if an analyst reevaluates their earnings estimate ahead of an earnings release, it means they likely have new information that could possibly be more accurate.

Now that we understand the basic idea, let's look at how the Expected Surprise Prediction works. The ESP is calculated by comparing the Most Accurate Estimate to the Zacks Consensus Estimate, with the percentage difference between the two giving us the Zacks ESP figure.

When we join a positive earnings ESP with a Zacks Rank #3 (Hold) or stronger, stocks posted a positive bottom-line surprise 70% of the time. Plus, this system saw investors produce roughly 28% annual returns on average, according to our 10 year backtest.

Stocks with a ranking of #3 (Hold), or 60% of all stocks covered by the Zacks Rank, are expected to perform in-line with the broader market. Stocks with rankings of #2 (Buy) and #1 (Strong Buy), or the top 15% and top 5% of stocks, respectively, should outperform the market; Strong Buy stocks should outperform more than any other rank.

Should You Consider Regeneron?The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to quickly look at a qualifying stock. Regeneron (REGN - Free Report) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $10.63 a share 21 days away from its upcoming earnings release on July 30, 2026.

Regeneron's Earnings ESP sits at +0.13%, which, as explained above, is calculated by taking the percentage difference between the $10.63 Most Accurate Estimate and the Zacks Consensus Estimate of $10.62. REGN is also part of a large group of stocks that boast a positive ESP. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

REGN is just one of a large group of Medical stocks with a positive ESP figure. Natera (NTRA - Free Report) is another qualifying stock you may want to consider.

Natera, which is readying to report earnings on August 6, 2026, sits at a Zacks Rank #3 (Hold) right now. Its Most Accurate Estimate is currently -$0.37 a share, and NTRA is 28 days out from its next earnings report.

For Natera, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of -$0.47 is +21.28%.

REGN and NTRA's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

-

Newly published study shows Signatera MRD-positive patients lived longer with adjuvant chemotherapy, while MRD-negative patients saw no significant benefit

First predictive data for overall survival from GALAXY trial in patients with oligo-metastatic CRC in the liver

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in JAMA Oncology, evaluating the utility of Signatera, its personalized molecular residual disease (MRD) test, in patients with resected colorectal liver metastases (CRLM). The data was also presented as an oral presentation at the 2026 European Society for Medical Oncology Gastrointestinal (ESMO GI) Congress.

The liver is the most common site of distant metastasis in colorectal cancer, and CRLM is a major cause of cancer-related mortality.1,2 In patients where curative-intent surgery is possible, the benefit of adjuvant chemotherapy (ACT) has been a point of debate and uncertainty.3 MRD status has previously been shown to predict a disease free survival (DFS) benefit from ACT, but not an overall survival (OS) benefit. This is the first dataset in a large cohort to show MRD test prediction of OS from ACT in this population.

The JAMA paper included 298 patients from the GALAXY trial, the prospective, observational arm of CIRCULATE-Japan. Outcomes were evaluated according to MRD status and whether patients received ACT, with a median follow-up of 43 months. Key findings included:

Signatera identified patients who derive a significant survival benefit from ACT. Among MRD-positive patients who underwent surgery without neoadjuvant chemotherapy, ACT was associated with improved DFS and OS compared to observation (OS: adjusted HR, 0.27; P=0.03; 48-month OS, 65.3% vs. 32.9%; DFS: adjusted HR, 0.07; P<0.0001). MRD-negative patients had favorable outcomes, with no observed survival benefit from ACT. Post-surgical MRD status was strongly prognostic. MRD positivity 2–10 weeks after surgery was associated with significantly worse DFS and OS, including those who received neoadjuvant chemotherapy before surgery (DFS: HR, 4.82; P<0.0001; OS: HR, 9.43; P<0.001), and those who did not (DFS: HR, 4.14; P<0.0001; OS: HR, 9.13; P<0.0001). “For patients with colorectal liver metastases, the benefit of ACT after curative-intent surgery has remained uncertain,” said Kozo Kataoka, M.D., Ph.D., division of lower GI, department of gastroenterological surgery, Hyogo Medical University, and senior author of the study. “Importantly, this is the largest analysis to show that post-surgical MRD status may help identify which patients benefit from ACT in patients who underwent upfront surgery.”

“This analysis adds important overall survival data in resected colorectal liver metastases, a setting where clinicians have historically had limited tools to determine who is most likely to benefit from ACT,” said Adham Jurdi, M.D., senior medical director of oncology at Natera. “It further reinforces how Signatera can help tailor treatment to each patient.”

References

Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015;41(9):729-41. Filho AM, Laversanne M, Ferlay J, Colombet M, Piñeros M, Znaor A, et al. The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 2025;156(7):1336-46. Adam R, Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg. 2019;3(1):50-6. About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

More News From Natera, Inc.

Back to Newsroom

CompaniesJune 29 (Reuters) - Genetic testing firm Natera (NTRA.O), opens new tab and cancer drug developer Aveta Biomics said on Monday they ​have partnered on a late-stage study ‌of an experimental therapy for head and neck cancer, in a bid to improve how patients' ​response to treatment is monitored.

Here are ​some details:

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

The study will test Aveta's ⁠APG-157, an experimental oral therapy designed to ​help the body fight tumors, in patients ​with locally advanced head and neck cancer.

Natera said its Signatera test will be used in the ​study to assess molecular residual disease ​and treatment response, and will serve as a secondary ‌endpoint.

The ⁠companies said the test will be used before, during and after treatment to monitor patients' response.

Aveta Biomics said the study will enroll about ​826 patients ​globally, ⁠including in North America, Europe, Asia-Pacific and Australia.

It said the study ​builds on data from a ​mid-stage ⁠trial showing the therapy helped control tumors and showed encouraging survival outcomes.

The trial is expected ⁠to ​begin enrollment in the ​second half of 2026, the companies said.

Reporting by Sahil ​Pandey in Bengaluru; Editing by Diti Pujara

Our Standards: The Thomson Reuters Trust Principles., opens new tab

-

First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting

Commercial launch expected by year-end, pending final reimbursement and pricing

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

This approval supports the use of Signatera for patients with colorectal cancer (CRC) in the adjuvant setting and makes Signatera the first PMDA-approved MRD test in Japan. Natera expects to commercially launch Signatera for CRC in Japan by the end of 2026, subject to final pricing determination.

More than 150,000 people are diagnosed with CRC in Japan each year,1 making it one of the country’s most common cancers. This disease burden is comparable to that of the United States and highlights the need for more individualized tools to help Japanese clinicians inform adjuvant treatment decisions. Approval of Signatera fulfills this unmet need.

Commercialization of Signatera will be supported by an existing position statement from the Japan Society of Clinical Oncology (JSCO) and guidance from the Japanese Society of Medical Oncology (JSMO), which recommends the use of MRD testing in CRC.

“This approval marks an important milestone for Japanese patients with colorectal cancer,” said Takayuki Yoshino, M.D., executive advisor to hospital director and director, department of global oncology, National Cancer Center Hospital East, chairman of JSCO, president of JSMO, and program director of the CIRCULATE-Japan Project. “Clinicians and medical societies in Japan deeply value the strength of the clinical evidence on Signatera, demonstrating its ability to inform treatment decisions.”

Regulatory approval was supported by positive evidence from the GALAXY clinical trial, which demonstrated that patients who test MRD-positive after surgery derive significant benefit from adjuvant chemotherapy, while those who test MRD-negative derive no benefit from adjuvant chemotherapy. With analysis of 2,240 samples, this is one of the largest and most comprehensive prospective studies of MRD testing in resectable CRC and is part of the CIRCULATE-Japan platform involving thousands of CRC patients and >150 Japanese institutions.

“We are grateful to the investigators and patients who helped build the clinical evidence supporting this milestone,” said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera. “As we prepare for commercial launch in CRC, we remain committed to expanding global access to Signatera across additional cancer types, with muscle-invasive bladder cancer representing our next planned submission in Japan.”

References

National Cancer Center Japan, Cancer Information Service, colorectal cancer statistics, 2023 incidence data.About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

More News From Natera, Inc.

Back to Newsroom